NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@fmc-a

Fresenius Medical Care places bonds with a volume of 750 million

Fresenius Medical Care, the world's leading provider of products

and services for individuals with kidney diseases, today successfully placed bonds with a volume of 750 million. The bonds with

a 5-year maturity and a coupon of 3.875% were issued at a price of 99.635% resulting in a yield of 3.957%.

The proceeds will be used for general corporate purposes, including

the refinancing of existing financial liabilities.

The bonds were drawn under the Debt Issuance Program (DIP) by Fresenius

Medical Care. The Company has applied to the Luxembourg Stock Exchange to admit the bonds to trading on its regulated market.

The envisaged settlement date is September 20, 2022.

Fresenius Medical Care is the world's leading provider of products

and services for individuals with renal diseases of which around 3.8 million patients worldwide regularly undergo dialysis treatment.

Through its network of 4,163 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 346,000 patients

around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along

with its core business, the Renal Care Continuum, the Company focuses on expanding in complementary areas and in the field of critical

care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the company's website at www.freseniusmedicalcare.com.

This announcement does not contain or constitute

an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, or the United

States of America (the "United States") or in any jurisdiction to whom or in which such offer or solicitation is unlawful.

The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities

Act") and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent such registration,

except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject

to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account

or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to herein

has not been and will not be registered under the applicable securities laws of Australia, Canada or Japan. There will be no public offer

of the securities in the United States.

This announcement has been prepared on the basis

that any offer of bonds in any Member State of the European Economic Area (each, a Member State) will only be made (i) pursuant to

a prospectus prepared by Fresenius Medical Care AG & Co. KGaA pursuant to Regulation (EU) 1129/2017 (as amended, the "Prospectus

Regulation"), as supplemented, or (ii) pursuant to an exemption under the Prospectus Regulation from the requirement to publish

a prospectus for offers of securities. Fresenius Medical Care has not authorized, nor does it authorize, the making of any offer of securities

in circumstances in which an obligation arises for Fresenius Medical Care or any other person to publish or supplement a prospectus for

This announcement is directed at and/or for distribution

only to persons who (i) are outside the United Kingdom; (ii) who have professional experience in matters relating to investments

falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"),

(iii) are high net worth entities falling within article 49(2)(a) to (d) of the Order; or (iv) other persons to whom

it may otherwise be lawfully communicated (all such persons together being referred to as "relevant persons"). This announcement

is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its

contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged

in only with relevant persons.

This announcement has been prepared on the basis

that any offer of bonds in the United Kingdom will only be made pursuant to an exemption under Section 86 of the Financial Services

and Markets Act 2000 from the requirement to publish a prospectus for offers of securities. Fresenius Medical Care has not authorized,

nor does it authorize, the making of any offer of securities in circumstances in which an obligation arises for Fresenius Medical Care

or any other person to publish or supplement a prospectus for such offer.

This announcement contains forward-looking statements

that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking

statements due to certain factors, e.g. impacts of COVID-19, changes in business, economic and competitive conditions, regulatory reforms,

results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability

of financing. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this announcement.

The information contained in this announcement

is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information

contained in this announcement or its accuracy or completeness. The information in this announcement is subject to change.